Avalo Therapeutics

Historical price data

Avalo Therapeutics is a U.S.-based, clinical-stage biotechnology company with a mission to develop and commercialize targeted therapeutics for significant unmet needs in immunology and immuno-oncology. Its core strategy involves advancing a pipeline of immune-modulating assets through clinical development, aiming for proof-of-concept data and strategic partnerships. The company operates as a public entity, navigating the high-risk, high-reward landscape of drug development, with its valuation heavily influenced by clinical trial catalysts and financing events.

Focused on developing targeted therapeutics, primarily monoclonal antibodies and small molecules, designed to modulate specific immune system pathways such as cytokine signaling and immune cell function.

In ALI/ARDS, Avalo competes against decades of failed trials but no approved drugs, offering a first-mover opportunity if successful. In IBD, it faces a crowded market dominated by major pharma companies with entrenched products. For its rare disease programs, the primary competition is supportive care, but commercial challenges in ultra-rare markets are significant.